Related Experiment Videos
[Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma].
1Charité - Campus Benjamin Franklin, Universitätsmedizin, Berlin. kurt.miller@charite.de
Aktuelle Urologie
|May 31, 2006
Summary
Docetaxel therapy significantly increases survival time for hormone-refractory prostate cancer, establishing it as a standard treatment. Consensus guidelines address its use, particularly for symptomatic patients, and therapy monitoring.
Area of Science:
- Oncology
- Medical Therapeutics
Background:
- Hormone-refractory prostate carcinoma (HRPC) presents a prognostic challenge due to non-uniform definitions.
- Docetaxel therapy has demonstrated increased survival in HRPC patients, becoming a standard treatment.
- The efficacy and patient selection for docetaxel in HRPC require clear guidelines.
Framework:
- An interdisciplinary consensus conference in summer 2005 addressed key questions regarding docetaxel therapy for HRPC.
- The 3-week chemotherapy regimen at 75 mg/m² was affirmed as the standard treatment for symptomatic patients.
- Discussions also focused on the appropriate use of chemotherapy in asymptomatic HRPC patients.
Implementation:
- Standardized recommendations for the administration and monitoring of docetaxel therapy were formulated.
- The consensus aimed to optimize treatment protocols for HRPC.
- Guidelines were established to ensure consistent and effective patient care.
Implications:
- Established standard therapy with docetaxel improves survival outcomes for hormone-refractory prostate cancer.
- Consensus guidelines provide a framework for clinical decision-making regarding docetaxel use in HRPC.
- Further clarification is needed on chemotherapy application for asymptomatic HRPC patients.